ABSTRACT
Liver metastasis of gastric cancer is the most common for hematogenous metastases and so fatal, that the identification of novel markers and targets for therapy are crucial. We conducted transcriptome analyses between synchronous liver metastasis, primary tumor, and adjacent tissues from four patients with metastasis confined to the liver to discover that GNG4 upregulated substantially in primary gastric cancer tissues. Quantitative RT-qPCR assay for 300 gastric cancer patients revealed that higher levels of GNG4 in primary cancer were associated with shorter overall survival and a higher risk of liver recurrence. The oncogenic phenotypes of GNG4 were determined by knockout and forced expression of GNG4. Tumor formation by GNG4 knockout cells was more strikingly attenuated in a liver metastasis mouse model compared with a subcutaneous model. GNG4 is a candidate for a therapeutic target for liver metastasis, and its expression may enable us to provide better disease monitoring for liver metastasis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Grant-in-Aid for Encouragement of Young Scientists (2017, B, 17K16538), the Japanese Society for Gastroenterological Carcinogenesis (2016), Nakayama Cancer Research Institute (2016), and the Yokoyama Foundation for Clinical Pharmacology (2016).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All informed consent for the use of clinical samples and data was obtained from all patients in written manners, consistent with the requirement Institutional Review Board at Nagoya University, Japan. All animal experiments were conducted consistent with the ARRIVE guidelines and were approved by the Animal Research Committee of Nagoya University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant support: This work was supported by a Grant-in-Aid for Encouragement of Young Scientists (2017, B, 17K16538), the Japanese Society for Gastroenterological Carcinogenesis (2016), Nakayama Cancer Research Institute (2016), and the Yokoyama Foundation for Clinical Pharmacology (2016).
Abbreviations: ERK1/2, extracellular signal-regulated kinase 1/2, GNG, G protein gamma; mRNA, messenger RNA; PI3K, phosphoinositide 3-kinase; RNAseq, RNA-sequencing; RT-PCR, reverse-transcription polymerase chain reaction; MRI, magnetic resonance imaging
Disclosures: The authors declare no conflicts of interest.
Transcript Profiling: None
Writing Assistance: We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Data Availability
Data is available in the manuscript and supplemental data. All other data will be available as needed unless related to personal information.
